Significant Sales Growth at Novo Nordisk
Novo Nordisk has announced a remarkable increase in sales, achieving a 25% growth in Danish kroner and a 26% increase at constant exchange rates, culminating in DKK 290.4 billion for 2024. This robust performance highlights the company's strong position in the healthcare market, particularly in diabetes and obesity treatments.
Impressive Financial Performance in 2024
The financial results for 2024 reflect an operating profit surge of 25%, amounting to DKK 128.3 billion. This growth was largely attributed to favorable gross-to-net sales adjustments in the US market, although the firm faced some challenges due to impairment losses.
Regional Sales Breakdown
In North America, Novo Nordisk's operations exhibited a striking 30% increase in sales both in local currency and at constant exchange rates. Meanwhile, international operations also saw a significant 17% uptick. The demand for diabetes and obesity care products boosted overall sales, with a notable 26% increase leading to DKK 271.8 billion in revenue.
Diabetes and Obesity Care Performance
Diabetes products saw impressive growth, led by a 21% increase in GLP-1 diabetes sales. Additionally, Novo Nordisk's obesity care segment surged by 56%, totaling DKK 65.1 billion. The company also experienced an increase of 9% in sales of rare disease treatments converging with its overall strategy.
Advancements in Research and Development
On the research front, 2024 proved to be a significant year for Novo Nordisk, with the CagriSema product demonstrating superior results in weight loss for adults battling obesity. The REDEFINE 1 trial reported an impressive weight loss average of 22.7% among participants. Moreover, semaglutide showed a 20.7% weight loss impact in the STEP UP obesity trial.
Acquisition of Catalent Manufacturing Sites
In a strategic move to expand its production capacity, Novo Nordisk completed the acquisition of three manufacturing sites from Novo Holdings in December 2024. This acquisition is expected to enhance the company's operational efficiency and support its growth ambitions.
Future Outlook for 2025
Looking ahead, Novo Nordisk anticipates a sales growth rate of 16-24% at constant exchange rates for 2025, with operating profit expected to rise by 19-27%. In kroner terms, sales and operating profit growth are projected to be 3 and 5 percentage points higher, respectively.
Dividends for Shareholders
At the upcoming Annual General Meeting slated for March 2025, the Board of Directors plans to propose a final dividend of DKK 7.90 per share for 2024. This follows an interim dividend of DKK 3.50 paid earlier, resulting in a total expected dividend increase of 21% for the year, reaching DKK 11.40 per share.
Messages from Leadership
Lars Fruergaard Jørgensen, president and CEO, expressed satisfaction with the 2024 performance, noting that over 45 million people are now benefiting from Novo Nordisk's treatments. He emphasized the company's focus on commercial execution and the expansion of its R&D pipelines, particularly in obesity treatment initiatives.
About Novo Nordisk
Novo Nordisk stands as a prominent global healthcare entity, founded in 1923 and based in Denmark. The organization's mission is to facilitate change in the treatment of serious chronic diseases, developing groundbreaking science while enhancing access to essential medications. With a workforce of around 76,300 in 80 countries, Novo Nordisk sells products in upwards of 170 countries. Their shares are publicly traded on Nasdaq Copenhagen with the ticker symbol Novo-B, and their ADRs are available on the New York Stock Exchange under the symbol NVO.
Frequently Asked Questions
What was Novo Nordisk's total sales in 2024?
Novo Nordisk reported total sales of DKK 290.4 billion for the year 2024.
How much did operating profit increase in 2024?
Operating profit rose by 25% in Danish kroner, amounting to DKK 128.3 billion.
What major acquisition did Novo Nordisk complete?
The company completed an acquisition of three manufacturing sites from Novo Holdings in December 2024.
What is the expected dividend for shareholders in 2024?
The Board of Directors is proposing a final dividend of DKK 7.90 per share, totaling DKK 11.40 when combined with interim payouts.
What advancements were made in R&D during 2024?
Novo Nordisk saw significant progress in its R&D efforts, particularly with CagriSema and semaglutide, showing substantial weight loss results in clinical trials.
